Carregant...
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Mepolizumab (Nucala(®)) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eosinophilic asthma by the US Food and Drug Administration (FDA), European Medicines Agency (EMA; European Union) and more recently Na...
Guardat en:
| Publicat a: | Biologics |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5498675/ https://ncbi.nlm.nih.gov/pubmed/28721009 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S93954 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|